Results 31 to 40 of about 60,894 (286)

Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001–2016

Pediatrics, 2020
Using population-based national surveillance data, we compared rates of IPD among children
T. Adebanjo, Tracy Pondo, D. Yankey, H. Hill, R. Gierke, M. Apostol, M. Barnes, S. Petit, M. Farley, L. Harrison, C. Holtzman, J. Baumbach, N. Bennett, S. McGuire, A. Thomas, W. Schaffner, B. Beall, C. Whitney, T. Pilishvili   +18 more
semanticscholar   +1 more source

Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006–18: prospective observational time-series and case-control studies

Lancet Global Health, 2020
Summary Background The population impact of pneumococcal conjugate vaccines (PCVs) depends on direct and indirect protection. Following Malawi's introduction of the 13-valent PCV (PCV13) in 2011, we examined its impact on vaccine and non-vaccine serotype
N. Bar-Zeev, T. Swarthout, D. Everett, M. Alaerts, J. Msefula, C. Brown, Sithembile Bilima, J. Mallewa, Carina King, A. von Gottberg, J. Verani, C. Whitney, C. Mwansambo, S. Gordon, N. Cunliffe, N. French, R. Heyderman   +16 more
semanticscholar   +1 more source

Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

New England Journal of Medicine, 2015
BACKGROUND Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal disease in infants, but their efficacy against pneumococcal community-acquired pneumonia in adults 65 years of age or older is unknown. METHODS In a randomized, double-blind,
M. Bonten, S. Huijts, M. Bolkenbaas, Chris Webber, S. Patterson, S. Gault, C. H. van Werkhoven, A. V. van Deursen, E. Sanders, T. Verheij, Michael Patton, A. McDonough, A. Moradoghli-Haftvani, Helen M Smith, Tracey Mellelieu, M. Pride, Graham R. Crowther, B. Schmoele-Thoma, D. Scott, K. Jansen, R. Lobatto, B. Oosterman, Nils Visser, E. Caspers, Andre Smorenburg, E. Emini, W. Gruber, D. Grobbee   +27 more
semanticscholar   +1 more source

A brief history of and future prospects for pneumococcal vaccination in Malaysia

Pneumonia, 2023
Pneumococcal pneumonia remains a significant global public health issue. Malaysia has recently added the 10 valent pneumococcal conjugate vaccine to its national immunisation programme.
Alex J. J. Lister, Evelin Dombay, David W. Cleary, Lokman H. Sulaiman, Stuart C. Clarke   +4 more
doaj   +1 more source

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults

Human Vaccines & Immunotherapeutics, 2019
Background: Pneumococcal disease remains a public health priority in adults. Safety and immunogenicity of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) containing 13 serotypes included in 13-valent pneumococcal conjugate ...
Helen L Stacey, Jeffrey Rosen, James T Peterson, A. Williams-Diaz, Vanita Gakhar, T. Sterling, C. Acosta, Katrina M. Nolan, Jianing Li, Alison Pedley, Patrice Benner, Chitrananda Abeygunawardana, Michael Kosinski, William J. Smith, H. Pujar, L. Musey   +15 more
semanticscholar   +1 more source

Doubly Robust Proximal Synthetic Controls [PDF]

arXiv, 2022
To infer the treatment effect for a single treated unit using panel data, synthetic control methods construct a linear combination of control units' outcomes that mimics the treated unit's pre-treatment outcome trajectory. This linear combination is subsequently used to impute the counterfactual outcomes of the treated unit had it not been treated in ...
arxiv  

Adesão às novas vacinas conjugadas. Vacina anti-meningocócica e anti-pneumocócica.

Acta Médica Portuguesa, 2004
The new conjugate vaccines against group C meningococcal infection and pneumococcal infection were introduced in Portugal in 2001. In 2001/2002, the media published several alarming news on meningococcal disease and there was an increased demand of those
Laurinda De Queirós, Luis Castro, Maria Carmo Ferreira, Guilherme Gonçalves   +3 more
doaj   +1 more source

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design

Clinical Infectious Diseases, 2018
Our study demonstrated real-world, direct effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia following introduction into a routine immunization program among adults aged ≥65 years, many of whom had
J. McLaughlin, Q. Jiang, R. Isturiz, H. Sings, D. Swerdlow, B. Gessner, R. Carrico, P. Peyrani, T. Wiemken, William A. Mattingly, J. Ramirez, L. Jodar   +11 more
semanticscholar   +1 more source

The interactions of SARS-CoV-2 with co-circulating pathogens: Epidemiological implications and current knowledge gaps [PDF]

arXiv, 2022
Despite the availability of effective vaccines, the persistence of SARS-CoV-2 suggests that co-circulation with other pathogens and resulting multi-epidemics may become increasingly frequent. To better forecast and control the risk of such multi-epidemics, it is essential to elucidate the potential interactions of SARS-CoV-2 with other pathogens; these
arxiv  

Genetic diversity of Streptococcus pneumoniae causing meningitis and sepsis in Singapore during the first year of PCV7 implementation

Emerging Microbes and Infections, 2014
Streptococcus pneumoniae is a major cause of sepsis, meningitis and respiratory disease worldwide. Pneumococcal conjugate vaccines (PCVs) have now been implemented in many countries worldwide, including Singapore.
Elita Jauneikaite, Johanna Mary Carnon Jefferies, Nicholas William Vere Churton, Raymond Tzer Pin Lin, Martin Lloyd Hibberd, Stuart Charles Clarke   +5 more
doaj   +1 more source